Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kinnander, G.
Right arrow Articles by Asplund, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kinnander, G.
Right arrow Articles by Asplund, K.

Stroke, Vol 18, 240-243, Copyright © 1987 by American Heart Association


ARTICLES

Beta-adrenergic blockade after stroke. A preliminary closed cohort study

G Kinnander, M Viitanen and K Asplund

To collect background data for a prospective clinical trial of beta- blocking agents in the prevention of deaths after stroke, the long-term prognosis in 60 patients discharged from a stroke unit on beta-blocker therapy was compared with the outcome in 60 matched patients with stroke but without beta-blockers. Matching included sex, age, type of stroke, and presence or absence of hypertension and cardiac failure. Thirteen patients (22%) in the beta-blocker group died during a median followup of 41 months. Of the 60 patients not on beta-blockade at discharge, 21 (35%) died during a median followup of 36 months. By life- table technique and log-rank test, the relative risk for death was 0.60:1.00 (p = 0.14). During followup, 12 recurrent strokes were observed in patients on beta-blockers and 19 in patients without beta- blockers (relative risk 0.57:1.00; p = 0.12). It appeared that the reduction in mortality could only marginally be ascribed to fewer deaths from myocardial infarction; other causes of death were also less frequent in beta-blocker-treated patients. The results emphasize that supplementary information on the effect of beta-blocking agents on mortality after stroke is needed before a larger trial of beta-blocker therapy in patients with manifest cerebrovascular disease can be initiated.


This article has been cited by other articles:


Home page
StrokeHome page
J. Prosser, L. MacGregor, K. R. Lees, H.-C. Diener, W. Hacke, S. Davis, and on behalf of the VISTA Investigators
Predictors of Early Cardiac Morbidity and Mortality After Ischemic Stroke
Stroke, August 1, 2007; 38(8): 2295 - 2302.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. Rashid, J. Leonardi-Bee, and P. Bath
Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review
Stroke, November 1, 2003; 34(11): 2741 - 2748.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
Y. Yamamoto, I. Akiguchi, K. Oiwa, M. Hayashi, and J. Kimura
Adverse Effect of Nighttime Blood Pressure on the Outcome of Lacunar Infarct Patients
Stroke, March 1, 1998; 29(3): 570 - 576.
[Abstract] [Full Text] [PDF]